June 21, 2005 -- Clinical Data Inc. will acquire Genaissance Pharmaceuticals Inc.in an all-stock deal valued at approximately $56 million. That is a surprisingly low value for a company that once boosted a valuation of nearly $1 billion. On the other hand, it is a significant 25% premium over its current value of $40 million. The history of Genaissance says a lot about the larger pharmacogenomics story. We detail the permutations of Genaissance - the high hopes on which it was founded, and its present incarnation...
